Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumors - An international double-blind, placebo-controlled randomized phase 2. Prodige 31 REMINET. A FFCD study

Affiliation auteurs!!!! Error affiliation !!!!
TitreLanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumors - An international double-blind, placebo-controlled randomized phase 2. Prodige 31 REMINET. A FFCD study
Type de publicationJournal Article
Year of Publication2021
AuteursLepage C., Phelip J.M, Lievre A., Le Malicot K., Dahan L., Tougeron D., Toumpanakis C., Di Fiore F., Lombard-Bohas C., Borbath I, Coriat R., Walter T.
JournalJOURNAL OF NEUROENDOCRINOLOGY
Volume33
Pagination139
Date PublishedFEB
Type of ArticleMeeting Abstract
ISSN0953-8194
Mots-clésClinical trial, duodeno-pancreatic, Maintenance, neuroendocrine tumor, non-resectable